Factors such as increase in awareness of hypercholesterolemia and cardiovascular diseases, changing lifestyle pattern, increase number of obese population and growing geriatric population are driving the growth of hypercholesterolemia drugs market globally.
The report titled “Hypercholesterolemia Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall hypercholesterolemia drugs market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug class and different geographical regions. Geographically, the global hypercholesterolemia drugs market is studied for the following regional markets:
Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hypercholesterolemia drugs market. Tools such as market positioning of key players, pipeline analysis and attractive investment proposition provide the readers with insights on the competitive scenario of the global hypercholesterolemia drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global hypercholesterolemia drugs market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global hypercholesterolemia drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Hypercholesterolemia Drugs Market Snapshot
2.2 Global Hypercholesterolemia Drugs Market, by Drugs Class
2.3 Global Hypercholesterolemia Drugs Market Share, by Geography, 2016 (Value %)
Chapter 3 Hypercholesterolemia Drugs Market Analysis
3.1 Global Hypercholesterolemia Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Hypercholesterolemia Drugs
3.4 Guidelines for Management of Hypercholesterolemia
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Hypercholesterolemia Drugs Market
Chapter 4 Global Hypercholesterolemia Drugs Market, by Drugs Class
4.1 Overview
4.2 Attractive Investment Proposition: Global Hypercholesterolemia Drugs Market, by Drugs Class
4.3 Top 3 Countries
4.4 HMG-CoA Reductase Inhibitors/ Statins
4.5 Bile Acid Sequestrants
4.6 Fibrates
4.7 Cholesterol Absorption Inhibitors
4.8 Other
Chapter 5 Global Hypercholesterolemia Drugs Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.2.2 North America Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.3.2 Europe Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.4.1 Asia Pacific Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.5.2 Latin America Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.6.2 Middle East and Africa Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
Chapter 6 Company Profiles
6.1 AbbVie Inc.
6.2 Aegerion Pharmaceuticals
6.3 Amgen Inc.
6.4 AstraZeneca
6.5 Eli Lilly and Company
6.6 Lupin Pharmaceuticals, Inc.
6.7 Merck & Co., Inc.
6.8 Pfizer Inc.
6.9 Sanofi S.A.
6.10 Shore Therapeutics, Inc.
6.11 Teva Pharmaceuticals
List of Tables :
TABLE 1 Market Positioning of Key Players in Global Hypercholesterolemia Drugs Market
TABLE 2 Global Hypercholesterolemia Drugs Market, by Drugs Class, 2015 – 2025 (US$ Bn)
TABLE 3 Top 3 Countries in Global Hypercholesterolemia Drugs Market, by Drugs Class 2015 – 2025 (US$ Bn)
TABLE 4 Global Hypercholesterolemia Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 5 North America Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 6 North America Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 7 Europe Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 8 Europe Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 9 Asia Pacific Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 10 Asia Pacific Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 11 Latin America Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 12 Latin America Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 13 Middle East and Africa Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 14 Middle East and Africa Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 15 AbbVie Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Aegerion Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Amgen Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 AstraZeneca: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Lupin Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Shore Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Teva Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
List of Figures :
FIG. 1 Hypercholesterolemia Drugs Market: Research Methodology
FIG. 2 Global Hypercholesterolemia Drugs Market, by Drugs Class, 2016 (US$ Bn)
FIG. 3 Global Hypercholesterolemia Drugs Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Hypercholesterolemia Drugs Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Hypercholesterolemia Drugs Market, by Drugs Class, 2016
FIG. 6 Global Hypercholesterolemia Drugs Market for HMG-CoA Reductase Inhibitors/ Statins, 2015 – 2025 (US$ Bn)
FIG. 7 Global Hypercholesterolemia Drugs Market for Bile Acid Sequestrants, 2015 – 2025 (US$ Bn)
FIG. 8 Global Hypercholesterolemia Drugs Market for Fibrates, 2015 – 2025 (US$ Bn)
FIG. 9 Global Hypercholesterolemia Drugs Market for Cholesterol Absorption Inhibitors, 2015 – 2025 (US$ Bn)
FIG. 10 Global Other Drugs in Hypercholesterolemia Drugs Market, 2015 – 2025 (US$ Bn)
Based on drug class, the global hypercholesterolemia drugs market is segmented as follows:
Hypercholesterolemia also known as high cholesterol, it is characterized by presence of high levels of cholesterol in the body that increases a risk of developing heart attack and stroke. Some factors such as changing lifestyle pattern, rising healthcare awareness, increase in number of obese population, growing incidence of hypercholesterolemia related diseases, growing awareness about cardiovascular diseases and rising geriatric population are primarily driving the growth of hypercholesterolemia drugs market globally. For the purpose of the study hypercholesterolemia drugs market is segmented on the basis of drug class such as HMG-CoA reductase inhibitors, bile acid sequestrants, fibric acid derivatives, cholesterol absorption inhibitors and others. It is studied that, among the considered market segment, statins is major revenue contributing segment because it’s recommended use in management of hypercholesterolemia due to their safety and effectiveness. Furthermore statins competitively inhibit HMG-CoA reductase which responsible for the production of cholesterol, moreover statins are involves in decreasing level of LDL cholesterol and increasing level of HDL cholesterol and thus most preferred in the hypercholesterolemia market.
For the purpose of this study, the hypercholesterolemia drugs market is categorized into:
Among the considered market segment, North America dominated the global Hypercholesterolemia market and growth was primarily driven by United States. Some factors such as sedentary lifestyle pattern, higher cost of medication, large number of target population, increasing risk of cardiovascular diseases and higher treatment awareness are prime factors that are assisting the market growth in North America. According to Centers for Disease Control and Prevention (CDC) more than 73.5 million adults (31.7%) in United States have high low-density lipoprotein. Nearly 31 million adult Americans have a total cholesterol level greater than 240 mg/dL. According to World Health Organization (WHO), over 50% of adults had raised total cholesterol in high-income countries; more than double the level of the low-income countries. It is estimated that Asia Pacific will show highest growth during forecast period due to rising healthcare awareness and changing lifestyle pattern would influence the market growth of hypercholesterolemia drugs.
